Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Retained Earnings: 2013-2024

Historic Retained Earnings for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$3.4 billion.

  • ImmunityBio's Retained Earnings fell 11.58% to -$3.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.7 billion, marking a year-over-year decrease of 11.58%. This contributed to the annual value of -$3.4 billion for FY2024, which is 13.96% down from last year.
  • ImmunityBio's Retained Earnings amounted to -$3.4 billion in FY2024, which was down 13.96% from -$3.0 billion recorded in FY2023.
  • ImmunityBio's Retained Earnings' 5-year high stood at -$1.6 billion during FY2020, with a 5-year trough of -$3.4 billion in FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$3.0 billion (2023), whereas its average is -$2.9 billion.
  • Data for ImmunityBio's Retained Earnings shows a maximum YoY plummeted of 143.91% (in 2020) over the last 5 years.
  • Over the past 5 years, ImmunityBio's Retained Earnings (Yearly) stood at -$1.6 billion in 2020, then decreased by 21.47% to -$2.0 billion in 2021, then declined by 21.23% to -$2.4 billion in 2022, then dropped by 24.52% to -$3.0 billion in 2023, then decreased by 13.96% to -$3.4 billion in 2024.